A Phase 2 interventional study of Nafamostat Low-Dose Group and Nafamostat High-Dose Group in Continuous Renal Replacement Therapy (CRRT), sponsored by Zhujiang Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-20.
Sponsored by Zhujiang Hospital · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a single-center, randomized, open-label, parallel-controlled clinical trial designed to investigate the anticoagulation efficacy and safety of different initial doses of Nafamostat Mesilate (NM) in ICU patients undergoing Continuous Renal Replacement Therapy (CRRT). Researchers will screen patients admitted to the Department of Critical Care Medicine at Zhujiang Hospital, Southern Medical University, to identify eligible participants based on inclusion and exclusion criteria. After obtaining informed consent, participants will be randomized into two groups On the basis of standardized CRRT treatment, the Low-Dose Group (Group A) will receive a continuous infusion of Nafamostat Mesilate at an initial dose of 20 mg/h, while the High-Dose Group (Group B) will receive an initial dose of 50 mg/h. The drug will be continuously infused pre-filter into the CRRT circuit. Dosage adjustments will be made for both groups to maintain target anticoagulation levels while ensuring that pre-filter safety limits are not exceeded. The primary outcome measure is filter lifespan, along with other secondary outcomes.
Investigational Drug: Nafamostat Mesilate for Injection.Study Title: Comparison of the Anticoagulant Efficacy of Different Doses of Nafamostat Mesilate During Continuous Renal Replacement Therapy in the Intensive Care Unit: A Single-Center, Randomized, Open-Label, Parallel-Controlled Clinical Trial.Principal Investigator: Professor Liu Zhanguo, Department of Critical Care Medicine, Zhujiang Hospital, Southern Medical University.Study Population: Adult patients aged 18 to 80 years admitted to the ICU who require CRRT treatment with an anticipated continuous dialysis duration of ≥24 hours; have essentially normal coagulation function (INR ≤1.5, fibrinogen ≥1.5 g/L, APTT ≤45 s); platelet count ≥50×10⁹/L; and a body mass index (BMI) between 18.5 and 25 kg/m².Exclusion Criteria: Known hypersensitivity to nafamostat mesilate, active bleeding, pregnancy, use of other systemic anticoagulants or extracorporeal devices (e.g., ECMO, IABP), or Child-Pugh class C liver dysfunction.Study Objectives: The primary objective is to determine whether a high dose (50 mg/h) of nafamostat mesilate, compared with a low dose (20 mg/h), prolongs filter lifespan in ICU patients undergoing CRRT. Secondary objectives include evaluating differences in transmembrane pressure, clotting events, CRRT duration, blood flow rates, delivered dose, and safety outcomes such as bleeding complications and adverse drug reactions.Study Design: A single-center, randomized, open-label, parallel-controlled clinical trial.Methods: Eligible patients will be randomized into two groups. The low-dose group (Group A) will receive nafamostat mesilate at an initial continuous infusion dose of 20 mg/h, while the high-dose group (Group B) will receive an initial dose of 50 mg/h. Nafamostat mesilate will be administered into the CRRT circuit pre-filter, followed by maintenance infusion at 20 mg/h (Group A) or 50 mg/h (Group B). Blood samples will be drawn to measure systemic and post-filter activated clotting time (ACT), as well as systemic activated partial thromboplastin time (APTT). Systemic ACT or APTT will be maintained at no more than 1.2 to 1.5 times the baseline value, whereas post-filter ACT or APTT will be maintained at 1.5 to 2.5 times baseline until CRRT discontinuation. Systemic ACT will be measured before CRRT initiation, at 2 hours and 8 hours after initiation, and systemic APTT will be measured at 24 hours. Based on monitoring results, the nafamostat mesilate dose will be adjusted in increments of 5 or 10 mg/h, with ACT rechecked 1 to 2 hours after each adjustment. From the second day onward, ACT will be monitored every 8 hours. Dose adjustments will be made to maintain systemic ACT and APTT at no more than 1.2 to 1.5 times baseline, and post-filter ACT or APTT at 1.5 to 2.5 times baseline. In the event of extracorporeal circuit clotting, progressive elevation of transmembrane pressure, excessively short filter lifespan in prior treatments, grade II or higher filter clotting, large clots in the venous chamber, or recurrent catheter occlusion, the dose may be increased at the discretion of the study physician. If systemic coagulation time or systemic ACT is markedly prolonged, or if liver function deteriorates due to the patient's underlying condition, the dose may be decreased after evaluating changes in systemic and post-filter ACT. The intervention will continue until CRRT is discontinued due to filter clotting, recovery, transfer, death, or bleeding. All patients will receive a standardized CRRT protocol (CVVH mode, blood flow rate 120-200 mL/min) and routine critical care management. Each filter may be used for up to 72 hours or until CRRT discontinuation.Sample Size: 92 patients (46 per group).Study Center: One center - Department of Critical Care Medicine, Zhujiang Hospital, Southern Medical University, Guangzhou, China.Primary Endpoint: Filter lifespan, defined as the duration (in hours) from initiation of nafamostat mesilate anticoagulation to filter replacement or CRRT discontinuation due to thrombosis, prolonged downtime, renal recovery, patient discharge, death, or bleeding events requiring a change in anticoagulation strategy.Secondary Endpoints:Filter performance: Changes in transmembrane pressure (TMP) at specified time intervals (2, 8, 16, 24 hours, etc.).Filter clotting events: Defined as TMP >250 mmHg or visible clotting.Treatment parameters: Total CRRT duration, mean daily blood flow rate, daily delivered dose, and total blood transfusion volume during treatment.Coagulation parameters: Maintenance of ACT and APTT within target ranges; changes in hemoglobin and platelet count.Safety outcomes: Incidence of bleeding complications (e.g., gingival bleeding, epistaxis, gastrointestinal bleeding); incidence of nafamostat mesilate-related adverse drug reactions (e.g., rash, hyperkalemia, elevated liver enzymes, gastrointestinal symptoms); total blood transfusion volume during CRRT.Safety Endpoints:Adverse events: Monitoring of specific adverse reactions, including drug allergy (rash), hyperkalemia, elevated AST/ALT, bleeding, thrombocytopenia, and gastrointestinal symptoms (nausea, vomiting, diarrhea).Serious adverse events (SAEs): Recording of any event resulting in death, life-threatening conditions, prolonged hospitalization, or significant disability, with assessment of causality related to the study drug.
Zhujiang Hospital is the lead sponsor of 202 studies on the registry; 96 are open to participants now.
Counted across the registry records on this site, refreshed daily.
The criteria were revised on the registry on Nov 18, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Nafamostat mesilate is administered at 20 mg/h into the CRRT circuit pre-filter (infused via a three-way connector at the blood inlet line) and continued as a maintenance infusion. The dose is adjusted in increments of 5 or 10 mg/h. Blood samples are drawn from both systemic and post-filter sites to measure activated clotting time (ACT) and activated partial thromboplastin time (APTT). Pre-filter ACT/APTT is maintained at no more than 1.2 to 1.5 times the baseline value. Post-filter ACT or APTT is maintained at 1.5 to 2.5 times the baseline until discontinuation of CRRT.
Drug: Nafamostat Low-Dose Group
Nafamostat mesilate is administered at 50 mg/h into the CRRT circuit pre-filter (infused via a three-way connector at the blood inlet line) and continued as a maintenance infusion. The dose is adjusted in increments of 5 or 10 mg/h. Blood samples are drawn from both systemic and post-filter sites to measure activated clotting time (ACT) and activated partial thromboplastin time (APTT). Pre-filter ACT/APTT is maintained at no more than 1.2 to 1.5 times the baseline value. Post-filter ACT or APTT is maintained at 1.5 to 2.5 times the baseline until discontinuation of CRRT.
Drug: Nafamostat High-Dose Group
Nafamostat Mesilate will be reconstituted using 5% Glucose Injection. For complete dissolution, at least 1 mL of solvent is added to the 10 mg vial, or at least 5 mL is added to the 50 mg vial. The resulting solution will be administered via continuous infusion into the CRRT circuit pre-filter (infused through a three-way stopcock connected to the blood inlet line of the dialysis circuit) at a maintained rate of 20 mg/h
Nafamostat Mesilate will be reconstituted using 5% Glucose Injection. For complete dissolution, at least 1 mL of solvent is added to the 10 mg vial, or at least 5 mL is added to the 50 mg vial. The resulting solution will be administered via continuous infusion into the CRRT circuit pre-filter (infused through a three-way stopcock connected to the blood inlet line of the dialysis circuit) at a maintained rate of 50 mg/h
Filter Lifespan
Defined as the duration (in hours) from the initiation of Nafamostat Mesilate anticoagulation in the CRRT circuit to the discontinuation of Nafamostat anticoagulation due to any of the following reasons: (i) Filter replacement; (ii) Termination of CRRT due to: filter clotting, prolonged filter downtime, renal recovery, patient transfer out of the ICU, or death; (iii) Discontinuation of Nafamostat anticoagulation due to adverse events such as bleeding, necessitating a change in the anticoagulation strategy. Data Source: Nursing records and medical charts.
Time frame: From the initiation of Nafamostat Mesilate anticoagulation until filterreplacement or discontinuation of CRRT (up to 72 hours per filter session).
Filter Transmembrane Pressure (TMP) Changes
TMP of the CRRT filter will be measured at the following time points after initiation of Nafamostat Mesilate anticoagulation: * Day 1: 2hours, 8hours, 16hours, 24hours * Day 2: 8hours, 16hours, 24hours (equivalent to 32hours, 40hours, 48hours from start) * Day 3: 8hours, 16hours, 24hours (equivalent to 56hours, 64hours, 72hours from start) Data obtained from nursing records and medical charts.
Time frame: From hour 0 (initiation of anticoagulation) to hour 72 (end of Day 3), with assessments at predefined hourly intervals.
Incidence of Filter Clotting Events
Defined as Transmembrane Pressure (TMP) exceeding 250 mmHg and/or visible clotting in the air collection chamber. Data obtained from nursing records and medical charts.
Time frame: From baseline (initiation of CRRT) up to 72 hours post-baseline, or until filter replacement/discontinuation, whichever occurs first.
Duration of CRRT
The total duration of the CRRT treatment session. Data obtained from nursing records and medical charts.
Time frame: From baseline (initiation of CRRT) up to 72 hours post-baseline, or until filter replacement/discontinuation, whichever occurs first.
Delivered CRRT Dose
The actual delivered dose of CRRT treatment. Data obtained from nursing records and medical charts.
Time frame: From initiation of CRRT until filter replacement or discontinuation, up to a maximum of 72 hours per session.
Activated Partial Thromboplastin Time (APTT)
APTT measured from peripheral venous blood. Data obtained from laboratory test results.
Time frame: At baseline (before CRRT), 2 hours post-baseline, 8 hours post-baseline, and at the last available measurement during treatment (up to 72 hours post-baseline).
Prothrombin Time (PT)
PT measured from peripheral venous blood. Data obtained from laboratory test results.
Time frame: At baseline (before CRRT), 2 hours post-baseline, 8 hours post-baseline, and at the last available measurement during treatment (up to 72 hours post-baseline).
Fibrinogen (FIB)
FIB measured from peripheral venous blood. Data obtained from laboratory test results.
Time frame: At baseline (before CRRT), 2 hours post-baseline, 8 hours post-baseline, and at the last available measurement during treatment (up to 72 hours post-baseline).
Activated Clotting Time (ACT)
ACT levels indicating systemic coagulation status and CRRT anticoagulation effect. Data obtained from laboratory test results.
Time frame: Pre-medication baseline, followed by assessments at 2hours, 8hours, 16hours, 24hours, 32hours, 40hours, 48hours, 56hours, 64hours, and 72hours post-initiation of anticoagulation.
Hemoglobin Level
Hemoglobin concentration measured from peripheral venous blood to assess anemia and guide transfusion timing during CRRT. Data obtained from laboratory test results.
Time frame: Before medication, Day 1, Day 2, and Day 3 after medication.
Platelet Count
Platelet count measured from peripheral venous blood to assess bleeding risk and monitor thrombocytopenia during CRRT. Data obtained from laboratory test results.
Time frame: Before medication, Day 1, Day 2, and Day 3 after medication.
Incidence of Bleeding Complications
Observation of bleeding manifestations such as gingival bleeding, epistaxis, skin ecchymosis, and gastrointestinal bleeding during CRRT. Data obtained from physician reports, nursing documents, and medical charts.
Time frame: From baseline (initiation of CRRT) up to 72 hours post-baseline, or until filter replacement/discontinuation, whichever occurs first.
Adverse Drug Reactions Related to Nafamostat
Includes drug allergy (rash), hyperkalemia, elevated AST/ALT, bleeding, decreased platelets, and gastrointestinal symptoms (nausea, vomiting, diarrhea). Data obtained from physician reports, nursing documents, and medical charts.
Time frame: From initiation of Nafamostat Mesilate up to 72 hours post-initiation.
Blood Transfusion Volume During Nafamostat-Anticoagulated CRRT
Total volume of blood or blood components (e.g., red blood cells, platelets, fresh frozen plasma, cryoprecipitate) transfused during the CRRT treatment period with Nafamostat anticoagulation. Data obtained from physician reports, nursing documents, and medical charts.
Time frame: From baseline (initiation of CRRT) up to 72 hours post-baseline, or until filter replacement/discontinuation, whichever occurs first.
Plan to share: No — Since some data may involve patients privacy. We have no plans to share data so far, and some data may be shared later depending on the patient's wishes.
No publications or documents are linked to this record.
Started Apr 2026 (actual). Primary completion is estimated for Mar 2027, 11 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.